Seqirus (Australia) Pty Ltd

16 PBAC submissions on file, active 2016–2024. 81% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Human papillomavirus 9-valent vaccine
  Vaccines · Recommended with restriction · 2022—
• Icosapent ethyl
  Cardiovascular · Recommended with restriction · 2024—
• Avacopan
  Immunology · Not recommended · 2024other sponsor
• Cationic ophthalmic emulsion, preservative free
  Ophthalmology · Recommended with restriction · 2020—
• Cell-cultured quadrivalent influenza vaccine (surface antigen, inactivated)
  Vaccines · Recommended with restriction · 2024—
• Ciclosporin
  Ophthalmology · Recommended with restriction · 2022other sponsor
• Inactivated quadrivalent influenza vaccine
  Vaccines · Recommended · 2016—
• Inactivated quadrivalent influenza vaccine (split virion)
  Vaccines · Recommended with restriction · 2020other sponsor
• Inactivated trivalent influenza vaccine (surface antigen), adjuvanted
  Vaccines · Recommended · 2018—
• Influenza vaccine, adjuvanted
  Vaccines · Noted · 2019—
• Influenza vaccine, adjuvanted quadrivalent and adjuvanted trivalent
  Vaccines · Noted · 2019—
• Quadrivalent influenza vaccine (surface antigen, inactivated, cell-based)
  Vaccines · Recommended with restriction · 2022—
• Riluzole
  Neurology · Recommended · 2018—
• Safinamide
  Neurology · Recommended with restriction · 2018—

Therapy area mix

Activity by year

2016 (1) · 2017 (1) · 2018 (4) · 2019 (2) · 2020 (1) · 2021 (1) · 2022 (2) · 2023 (1) · 2024 (3)

Rejection patterns

Across 3 Not recommended decisions on file.

• 1×Inadequate evidence of comparative benefit for remission at 26 weeks
• 1×insufficient evidence for maintenance therapy use from 26-52 weeks
• 1×uncertainties regarding additive benefit to rituximab in maintenance phase
• 1×limited longer-term safety and efficacy data
• 1×clinical claim of superiority not adequately supported for maintenance therapy